Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glymera (PB1023) in Inadequately Treated Type 2 Diabetes Mellitus
NCT01658501Phase 2Completed
- Sponsor
- PhaseBio Pharmaceuticals
- Start
- Jul 2012
- Primary completion
- Jul 2013
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of froniglutide in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by PhaseBio Pharmaceuticals. Primary endpoint: Change from baseline in hemoglobin A1c at 20 weeks. Started Jul 2012; status: completed.
02
Drugs
froniglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01658501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01658501.